Check the Ozempic pen
Survodutide , another GLP-1/glucagon dual agonist from Boehringer Ingelheim, is advancing through clinical trials
The high demand for the drug has provided a window of opportunity for the black market to create an illegal, knock-off version of Ozempic, which they claim to provide all of the benefits of the regulated medication for a lower price
Those can even be telehealth visits
Nutrition needs more thought with CKD, particularly around protein intake in later stages
To view a copy of this license, visit About this article Cite this article Benedict, C., Barclay, J., Ott, V